2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone has been researched along with Glioblastoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eyre, HJ; McCracken, JD; Neilan, BA; O'Bryan, RM; Taylor, SA | 1 |
1 other study(ies) available for 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone and Glioblastoma
| Article | Year |
|---|---|
Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Cerebellar Neoplasms; Cyclohexenes; Drug Evaluation; Ependymoma; Female; Glioblastoma; Humans; Male; Medulloblastoma; Middle Aged; Neoplasm Staging; Oligodendroglioma; Risk | 1985 |